Summary & Overview
HCPCS Level II J3403: Revakinagene taroretcel-lwey, per implant
HCPCS Level II code J3403 designates Revakinagene taroretcel-lwey billed per implant, reflecting an implantable biologic or cellular therapy product. As advanced therapies expand, accurate coding for per-implant products matters for standardized billing, clinical registry tracking, and payer coverage determinations across the United States.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on what the code represents, typical sites of service, and common modifiers used with HCPCS Level II injectable and implantable product codes. The publication also summarizes expected benchmarking topics: allowable pricing and reimbursement considerations, claim adjudication patterns across major national payers, and coding nuances specific to per-implant biologic therapies.
The piece provides clinical context for implantable cellular or gene-related therapies and outlines the policy and billing items readers should monitor, including coverage criteria, prior authorization trends, and documentation expectations. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J3403 represents Revakinagene taroretcel-lwey, per implant. This code denotes a biologic or cellular therapy product billed on a per-implant basis, indicating the service is the provision or implantation of a therapy device or biologic prepared as an implantable treatment.
-
Service type: Implantable biologic/cellular therapy
-
Typical site of service: Ambulatory surgical center or hospital outpatient setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving implantation of a biologic cell-based device labeled as Revakinagene taroretcel-lwey, billed per implant with HCPCS Level II code J3403. The usual clinical workflow begins with evaluation in a specialty clinic (orthopedics, pain management, or plastic/reconstructive surgery) for indications such as focal tissue loss, chronic nonhealing wound, or localized degenerative joint/cartilage defect where a cell-based implant is appropriate. Pre-procedure assessment includes confirmation of indication, consent, medication reconciliation, and baseline imaging (X-ray, MRI, or ultrasound) performed in an outpatient imaging center or hospital outpatient department.
On the day of service the patient is brought to an ambulatory surgery center or hospital operating room for sterile implant placement. Anesthesia may range from local with sedation to general, depending on site and complexity. The implant is prepared per manufacturer instructions and placed into the defect or implant pocket. Intraoperative documentation must record implant lot/serial, implant site, laterality, and any complications. Recovery occurs in the PACU with discharge to home same day for ambulatory cases or admission for overnight observation if clinically indicated. Post-procedure care includes activity restrictions, wound checks, and scheduled follow-up for functional assessment and potential imaging to evaluate incorporation of the implant.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|